Transition Therapeutics Inc. Study on Type 2 Diabetes Better Than Expected

Published: Apr 30, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Transition Therapeutics Inc said an early-stage study of its experimental type 2 diabetes drug showed significant improvement in blood sugar control and reductions in body weight, sending its shares up more than 65 percent. A once-weekly administered dose of the drug, codenamed TT-401, showed an acceptable safety and tolerability profile for all doses. The drug was tested in five doses on diabetic patients and in one dose on non-diabetic obese patients, the company said.

Help employers find you! Check out all the jobs and post your resume.

Back to news